Skip to main content
SpringerLink
Log in

Effect of allogeneic tumor cells, interleukin-2 and interleukin-6, on the growth of subcutaneous syngeneic tumors

  • Original Articles
  • Allogeneic Tumors, Cytokines, IL-2, IL-6
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

In the present study we demonstrate the ability of allogeneic M3 tumor cells to induce an antitumor response against the syngeneic tumor, when injected locally together with syngeneic B16 melanoma cells. The replacement of the allogeneic tumor cells with either syngeneic or allogeneic splenocytes had no effect on the growth of the syngeneic tumor. Systemic administration of both interleukin-2 (IL-2) and IL-6 did not affect the antitumor response induced by allogeneic tumor cells. When mice, previously injected with B16 and M3 cells, were rechallenged subcutaneously with B16 tumor cells at a different anatomical site, an inhibitory effect in some, but not all, experiments was observed. Systemic injections of either IL-2 or IL-6 did not alter the antitumor effects of the allogeneic and syngeneic tumor-cell mixtures. The significance of our results in developing immunotherapy modalities based on active immunization with allogeneic tumor cells and selected cytokines is discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Belldegrun A, Webb DE, Howard AA, Steinberg AM, Linehan WM, Rosenberg SA (1989) Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pretherapy nephrectomy. J Urol 141: 499

    PubMed  Google Scholar 

  2. Eisenthal A, Rosenberg SA (1989) Systemic induction of ADCC following administration of interleukin-2. Cancer Res 49: 6953

    PubMed  Google Scholar 

  3. Eisenthal A, Rosenberg SA (1989) The effect of various cytokines on the in vitro induction of ADCC in murine cells: enhancement of the IL-2 induced ADCC activity by IL-1. J Immunol 142: 2307

    PubMed  Google Scholar 

  4. Eisenthal A, Lafreniere R, Lefor AT, Rosenberg SA (1987) The effect of anti B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases. Cancer Res 47: 2771

    PubMed  Google Scholar 

  5. Eisenthal A, Shiloni E, Rosenberg SA (1988) Characterization of interleukin-2 induced murine cells which exhibit ADCC activity. Cell Immunol 115: 257

    PubMed  Google Scholar 

  6. Eisenthal A, Cameron RB, Rosenberg SA (1990) Induction of ADCC in vivo by alpha-IFN and its anti-tumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody. J Immunol 144: 4463

    PubMed  Google Scholar 

  7. Eisenthal A, Kashtan H, Rabau M, Ramakrishna V, Chaitchik S, Skornick Y (1993) Antitumor effects of interleukin-6 expressed in eukaryotic cells. Cancer Immunol Immunother 36: 101

    PubMed  Google Scholar 

  8. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, Frost P (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60: 397

    PubMed  Google Scholar 

  9. Gehan EA (1965) A generalized Wilcoxon test for comparing arbitrarily single censored samples. Biometrica 52: 203

    Google Scholar 

  10. Gracomini P, Aguzzi A, Pestka S, Fischer PB, Ferrone S (1984) Modulation by recombinant leukocyte (alpha) and fibroblast (beta) interferons of the expression and shadding of HLA- and tumor-associated antigens by human melanoma cells. J Immunol 133: 1649

    PubMed  Google Scholar 

  11. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine activated killer cell phenomenon: lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous peripheral blood lymphocytes. J Exp Med 155: 1823

    PubMed  Google Scholar 

  12. Hart I (1979) The selection and characterization of an invasive variant of the B16 melanoma. Am J Pathol 97: 587

    PubMed  Google Scholar 

  13. Hauser GJ, Zakuth V, Rosenberg H, Bino T, Spirer Z (1985) Interleukin-2 production by cord blood lymphocytes stimulated with mitogens and in mixed leukocyte culture. J Clin Lab Immunol 16: 371

    Google Scholar 

  14. Hurrel SM, Zarling JM (1983) Lyt2+ effectors cytotoxic for syngeneic tumor cells: generation by allogeneic stimulation and by supernatants from mixed lymphocyte cultures. J Immunol 131: 1017

    PubMed  Google Scholar 

  15. Itoh K, Tilden AB, Balch CM (1986) Lysis of human solid tumor cells by lymphokine-activated natural killer cells. J Immunol 136: 3910

    PubMed  Google Scholar 

  16. Kawase I, Komuta K, Namba M, Yokota S, Ogura T, Kishimoto S (1986) Macrophage tumoricidal activity as a possible antitumor mechanism associated with the local injection of allogeneic spleen cells into rat. Cancer Res 46: 1047

    PubMed  Google Scholar 

  17. Kishimoto T (1985) Factors affecting B-cell growth and differentiation. Annu Rev Immunol 3: 133

    PubMed  Google Scholar 

  18. Kitahara M, Kishimoto S, Hirano T, Kishimoto T, Okada M (1990) The in-vivo anti-tumor effect of human recombinant interleukin-6. Jpn J Cancer Res 81: 1032

    PubMed  Google Scholar 

  19. Lefor AT, Eisenthal A, Rosenberg SA (1988) Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts and modified syngeneic blasts. J Immunol 140: 4062

    PubMed  Google Scholar 

  20. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA (1986) High dose recombinant interleukin-2 in the treatment of patients with disseminated cancer: responses treatment related morbidity and histologic findings. J Am Med Assoc 256: 3117

    Google Scholar 

  21. Matory YL, Chang AE, Lipford III EH, Braziel R, Hyatt CL, McDonald HD, Rosenberg SA (1985) Toxicity of recombinant human interleukin-2 in rats following intravenous infusion. J Biol Response Mod 4: 377

    PubMed  Google Scholar 

  22. Mule JJ, Shu S, Rosenberg SA (1985) The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in-vivo. J Immunol 135: 646

    PubMed  Google Scholar 

  23. Mule JJ, Yang JC, Lafreniere R, Shu S, Rosenberg SA (1987) Identification of cellular mechanisms operational in-vivo during the regression of established pulmonary metastases by systemic administration of high dose recombinant interleukin-2. J Immunol 139: 285

    Google Scholar 

  24. Mule JJ, McKintosh JK, Jablons DM, Rosenberg SA (1990) Antitumor activity of recombinant interleukin 6 in mice. J Exp Med 171: 629

    PubMed  Google Scholar 

  25. Papa MZ, Mule JJ, Rosenberg SA (1986) Anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in-vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and non-immunogenic murine tumors of three distinct histologic types. Cancer Res 46: 4973

    PubMed  Google Scholar 

  26. Parmiani G, Sensi L, Carbone G, Colombo M, Pierotti M, Ballinari D, Hilgers J, Hilkens J (1982) Cross-reactivity between tumor cells and allogeneic normal tissues. Inhibition of a syngeneic lymphoma outgrowth in H-2 and non H-2 alloimmune Balb/c. Int J Cancer 29: 323

    PubMed  Google Scholar 

  27. Rosenberg SA, Grimm EA, McGrogan M, Doyle M, Kawasaki E, Koths K, Mark DF (1984) Biological activity of recombinant human interleukin 2 produced inEscherichia coli. Science 223: 1412

    PubMed  Google Scholar 

  28. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM (1985) Observations on the systemic administration of autologous lymphokine activated killer cells and recombinant interleukin-2 in patients with metastatic cancer. N Engl J Med 313: 1485

    PubMed  Google Scholar 

  29. Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz SL (1985) Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 161: 1169

    PubMed  Google Scholar 

  30. Rosenberg SA, Spiess PJ, Lafreniere R (1986) A new approach to adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318

    PubMed  Google Scholar 

  31. Rosenberg SA, Packard BS, et al (1988) Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319: 1676

    PubMed  Google Scholar 

  32. Schirrmacher V, Leidig S, Griesbach A (1991) In situ activation of syngeneic tumour-specific cytotoxic T lymphocytes: intra-pinna immunization followed by restimulation in the peritoneal cavity. Cancer Immunol Immunother 33: 299

    PubMed  Google Scholar 

  33. Spiess PJ, Yang JC, Rosenberg SA (1988) Tumor infiltrating lymphocytes expanded in recombinant interleukin-2 mediate potent antitumor activity in-vivo. Cancer Res 48: 206

    PubMed  Google Scholar 

  34. Steller EP, Eggermont AMM, Matthews W, Sugarbacker PH (1986) Recruitment of inflammatory cells to a tumor deposit potentiates the immunotherapeutic effects of interleukin-2. Cancer Immunol Immunother 23: 165

    PubMed  Google Scholar 

  35. Stovroff MC, Fraker DL, Swedenborg JA, Norton JA (1988) Cachectin/tumor necrosis factor: a possible mediator of cancer anorexia in the rat. Cancer Res 48: 4567

    PubMed  Google Scholar 

  36. Topelian SL, Muul LM, Solomon D, Rosenberg SA (1987) Expansion of tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods 102: 127

    PubMed  Google Scholar 

  37. Utsumi K, Takai Y, Tada T, Ohzeki S, Fujiwara H, Hamaoka T (1990) Enhanced production of IL-6 in tumor-bearing mice and determination of cells responsible for its augmented production. J Immunol 145: 397

    PubMed  Google Scholar 

  38. Weber JS, Rosenberg SA (1988) Modulation of murine tumor MHC antigens by cytokines in-vivo and in-vitro. Cancer Res 48: 5818

    PubMed  Google Scholar 

  39. Weber JS, Jay G, Tanaka K, Rosenberg SA (1987) Immunotherapy of a murine tumor with interleukin-2: increased sensitivity after MHC class I gene transfection. J Exp Med 166: 1716

    PubMed  Google Scholar 

  40. Weiden PL, Fluornoy N, Thomas ED, Prentice R, Fefer A, Buchner CD, Storb R (1979) Antileukemic effect of graft-versus-host discase in human recipients of allogeneic-marrow grafts. N Engl J Med 300: 1068

    PubMed  Google Scholar 

  41. Yang JJ, Perry-Lalley D, Rosenberg SA (1990) An improved method for growing murine tumor-infiltrating lymphocytes with in-vivo antitumor activity. J Biol Response Mod 9: 149

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Oncology Institute, Tel-Aviv Sourasky Medical Center, 6 Weizmann Street, 64239, Tel-Aviv, Israel

    Avi Eisenthal, Ofer Merimsky, Ronit Hirsch, Ilan Ron & Samario Chaitchik

  2. Department of Surgery A, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel

    Yehuda Skornick

  3. Dana Children's Hospital, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel

    Vera Zakut

Authors
  1. Avi Eisenthal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yehuda Skornick
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ofer Merimsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ronit Hirsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vera Zakut
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ilan Ron
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Samario Chaitchik
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This study was supported by a grant from the Israeli Cancer Association

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eisenthal, A., Skornick, Y., Merimsky, O. et al. Effect of allogeneic tumor cells, interleukin-2 and interleukin-6, on the growth of subcutaneous syngeneic tumors. Cancer Immunol Immunother 37, 233–239 (1993). https://doi.org/10.1007/BF01518516

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01518516

Key words

Search

Navigation